An open portfolio of interoperable, industry leading products
The Dotmatics digital science platform provides the first true end-to-end solution for scientific R&D, combining an enterprise data platform with the most widely used applications for data analysis, biologics, flow cytometry, chemicals innovation, and more.
In this webinar, we cover how to design and find the appropriate sample size for two common Phase II methods: Simon’s Two-Stage Design and MCP-Mod.
Phase II clinical trials are usually the first opportunity to investigate the efficacy of a new treatment in human subjects. Phase II trials provide valuable insights into the potential efficacy and the potential optimal dose for a proposed drug and the information gathered is increasingly used directly in Phase III trials.
However, Phase II is also the most common step at which treatment fails to show sufficient promise and thus good study design is vital to ensure this decision is made properly. Despite this statistical methods have been relatively underdeveloped but the acceptance from the FDA & EMA of recent statistical innovations such as MCP-Mod provides a greater chance to make phase II studies more effective and help make better phase III trials.
The Simon's two-stage design is one of the most commonly used phase II designs as it controls the Type I and II error while being optimal terms of the expected sample size being minimized if the regimen has low activity under the null hypothesis.
This webinar explains the theory behind Simon’s Two-Stage Design and how to plan the study using this design using a practical example.
MCP-Mod (Multiple Comparisons & Modelling) is an increasingly popular statistical methodology for model-based design and analysis of dose-finding studies in Phase IIb trials. Its strength lies in providing flexibility in characterizing the expected dose-response curve by allowing multiple models to be evaluated at the same time while still giving results which are efficient and control the error rates.
Since its development at Novartis, MCP-Mod promises to devise proof-of-concept and dose-ranging trials which generate superior statistical evidence for dose-selection, while providing safety and efficacy data that can prove critical data for Phase III clinical trial design.
This webinar explains the theory behind MCP-Mod and how to plan a study using this method using a practical example.
Duration: 60 minutes
Nothing showing? Click here to accept marketing cookies
If you don't have time to watch the webinar, you can read more about MCP-Mod, in a recent blog post MCP-Mod (Multiple Comparisons - Modelling) Explained
These Stories on Guide to Sample Size
Copyright © Statsols. All Rights Reserved. Do Not Sell or Share My Personal Information | Privacy Policy | License Agreement | Legal Disclaimers
No Comments Yet
Let us know what you think